Ticker

Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) insider David Malcom Rodman sold 2,170 shares of the stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $27.38, for a total value of $59,414.60. Following the sale, the insider directly owned 76,140 shares in the company, valued at

CEO Jon Congleton sold 75,000 shares for a total transaction value of ~$1.97 million on April 2, 2026. The sale represented 9.61% of direct holdings prior to the transaction, reducing direct ownership to 705,051 shares.

Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) CEO Jon Congleton sold 75,000 shares of the company's stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $26.27, for a total transaction of $1,970,250.00. Following the sale, the chief executive officer owned 705,051 shares of the company's stock,

RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced the appointment of Jeffrey A.

Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript